The stock of Arcutis Biotherapeutics Inc (ARQT) has gone up by 7.87% for the week, with a -0.52% drop in the past month and a -5.57% drop in the past quarter. The volatility ratio for the week is 3.77%, and the volatility levels for the past 30 days are 3.08% for ARQT. The simple moving average for the past 20 days is 3.49% for ARQT’s stock, with a 13.78% simple moving average for the past 200 days.
Is It Worth Investing in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Right Now?
The 36-month beta value for ARQT is at 1.78. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ARQT is 104.81M, and currently, shorts hold a 16.01% of that float. The average trading volume for ARQT on June 11, 2025 was 2.31M shares.
ARQT) stock’s latest price update
Arcutis Biotherapeutics Inc (NASDAQ: ARQT)’s stock price has gone rise by 3.06 in comparison to its previous close of 13.89, however, the company has experienced a 7.87% increase in its stock price over the last five trading days. globenewswire.com reported 2025-06-10 that Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE.05% in infants as young as 3 months to less than 2 years with atopic dermatitis Atopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis develop symptoms within their first year WESTLAKE VILLAGE, Calif., June 10, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first child has been enrolled in a Phase 2 open-label study, INTEGUMENT-INFANT, evaluating the safety and tolerability of investigational ZORYVE (roflumilast) cream 0.05% in infants aged 3 months to less than 24 months with atopic dermatitis (AD) applied once daily over a four-week period.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with H.C. Wainwright repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $15. The rating they have provided for ARQT stocks is “Buy” according to the report published on August 28th, 2024.
Mizuho gave a rating of “Buy” to ARQT, setting the target price at $8 in the report published on January 03rd of the previous year.
ARQT Trading at 1.77% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.35% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Heron Patrick J, who purchase 1,890 shares at the price of $13.32 back on Jun 04 ’25. After this action, Heron Patrick J now owns 24,424 shares of Arcutis Biotherapeutics Inc, valued at $25,177 using the latest closing price.
Heron Patrick J, the Director of Arcutis Biotherapeutics Inc, purchase 378 shares at $13.41 during a trade that took place back on Jun 05 ’25, which means that Heron Patrick J is holding 24,802 shares at $5,069 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -0.57 for the present operating margin
- 0.88 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -0.61. The total capital return value is set at -0.48. Equity return is now at value -70.58, with -31.54 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -1.0. The debt to equity ratio resting at 0.78. The interest coverage ratio of the stock is -7.26.
Currently, EBITDA for the company is -109.62 million with net debt to EBITDA at -0.54. When we switch over and look at the enterprise to sales, we see a ratio of 8.3. The receivables turnover for the company is 2.49for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.55.
Conclusion
In conclusion, Arcutis Biotherapeutics Inc (ARQT) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
